374Water (SCWO) 10-K 9 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 09, 2021	Jun. 30, 2020
Document and Entity Information:
Entity Registrant Name	POWERVERDE, INC.
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Entity Central Index Key	0000933972
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		31,750,106
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Public Float			$ 2,152,000
Entity Interactive Data Current	Yes
Entity File Number	000-27866
Entity Incorporation, State or Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash	$ 95,386	$ 20,033
Accounts receivable - related party	13,000	6,000
Prepaid expenses	22,000	11,460
Total Current Assets	130,386	37,493
Current Liabilities:
Accounts payable and accrued expenses	76,381	101,131
Convertible notes payable to related parties and stockholders, net of debt discount and issuance costs	194,422	0
Convertible notes payable, net of debt discount and issuance costs	97,176	0
Total Current Liabilities	367,979	101,131
Long Term Liabilities
Convertible notes payable to related parties and stockholders, net of debt discount and issuance costs, less current portion	20,536	211,900
Convertible notes payable, net of debt discount and issuance costs, less current portion	203,851	94,354
Total Long Term Liabilities	224,387	306,254
Total Liabilities	592,366	407,385
Commitments and Contingencies (Notes 5 and 10)
Stockholders' Deficit
Preferred stock: 50,000,000 preferred shares authorized, 0 preferred shares issued at December 31, 2020 and 2019	0	0
Common stock: 200,000,000 common shares authorized, par value $0.0001 per share, 40,455,468 common shares issued; 27,878,060 and 31,750,106 shares outstanding at December 31, 2020 and December 31, 2019, respectively	3,997	3,981
Additional paid-in capital	13,431,536	12,689,980
Treasury stock, 12,577,408 and 8,550,000 common shares at cost, respectively	(791,139)	(491,139)
Accumulated deficit	(13,106,374)	(12,572,714)
Total Stockholders' Deficit	(461,980)	(369,892)
Total Liabilities and Stockholders' Deficit	$ 130,386	$ 37,493

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Assets
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	40,455,468	40,455,468
Common Stock, shares outstanding	27,878,060	31,750,106
Treasury stock	12,577,408	8,550,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues [Abstract]
Revenue - related party	$ 40,000	$ 24,000
Operating Expenses
Research and development	114,559	218,919
General and administrative	323,806	217,510
Total Operating Expenses	438,365	436,429
Loss from Operations	(398,365)	(412,429)
Other Expenses
Loss on impairment	0	(69,178)
Interest expense	(135,295)	(33,309)
Total Other Expenses	(135,295)	(102,487)
Loss before Income Taxes	(533,660)	(514,916)
Provision for Income Taxes	0	0
Net Loss	$ (533,660)	$ (514,916)
Net Loss per Share - Basic and Diluted	$ (0.01)	$ (0.02)
Weighted Average Common Shares Outstanding - Basic and Diluted	30,742,649	31,750,106

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 3,981	$ 12,609,980	$ (491,139)	$ (12,057,798)	$ 65,024
Balance, Shares at Dec. 31, 2018	31,750,106
Stock based compensation		80,000			80,000
Net loss				(514,916)	(514,916)
Balance at Dec. 31, 2019	$ 3,981	12,689,980	(491,139)	(12,572,714)	(369,892)
Balance, Shares at Dec. 31, 2019	31,750,106
Repurchase of Common Stock Shares from related party, value			(300,000)		(300,000)
Repurchase of Common Stock Shares from related party, Shares	(4,027,408)
Issuance of common stock upon warrant exercise, value	$ 3	2,997			3,000
Issuance of common stock upon warrant exercise, Shares	25,000
Conversion of note payable and accrued interest, value	$ 13	26,059			26,072
Conversion of note payable and accrued interest, shares	130,362
Beneficial Conversion Feature on Convertible Notes Payable		712,500			712,500
Net loss				(533,660)	(533,660)
Balance at Dec. 31, 2020	$ 3,997	$ 13,431,536	$ (791,139)	$ (13,106,374)	$ (461,980)
Balance, Shares at Dec. 31, 2020	27,878,060

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows from Operating Activities
Net loss	$ (533,660)	$ (514,916)
Adjustments to reconcile net loss to net cash provided (used) by operating activities:
Impairment of intangible assets	0	69,178
Depreciation and amortization	0	5,633
Amortization of debt issuance costs	13,530	7,254
Amortization of debt discount	59,327	0
Stock based compensation		80,000
Changes in operating assets and liabilities
Accounts receivable with related party and prepaid expenses	(17,540)	3,406
Accounts payable and accrued expenses	(23,679)	61,996
Cash Used In Operating Activities	(502,022)	(287,449)
Cash Flows from Financing Activities
Proceeds from convertible notes payable, related parties and stockholders	125,000	200,000
Proceeds from convertible notes payable	761,000	125,000
Payments for debt issuance costs	(11,625)	(26,000)
Proceeds from warrant exercise	3,000	0
Payment for stock repurchase from related party	(300,000)	0
Cash Provided by Financing Activities	577,375	299,000
Net Change in Cash	75,353	11,551
Cash at Beginning of Period	20,033	8,482
Cash at End of Period	95,386	20,033
Supplemental Disclosure of Cash Flow Information
Cash paid during the period for interest	62,438	25,871
Cash paid during the period for income taxes	0	0
Non-cash Financing Activities
Beneficial conversion feature on convertible notes payable	712,500	0
Conversion of convertible note payable with related party and accrued interest	$ 26,072	$ 0

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2020
Financial Statements
Nature of Business	Note 1 – Nature of Business PowerVerde, Inc. (the “Company”) is a “C” Corporation organized under the Laws of Delaware with operations in Scottsdale, Arizona. The Company’s two founders, now its largest shareholders, have conceived and developed the use of a power systems patent. For several years, the Company has been undertaking research and development on a power generating system based on the patent and related intellectual property, which it hopes to commercialize. The Company has not generated revenues from its planned operations. During the years ended December 31, 2020 and 2019, the Company’s revenues have been generated from an assembly agreement with a related party.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2020
Going Concern:
Going Concern	Note 2 – Going Concern The financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As of December 31, 2020, the Company had a working capital deficit of $237,593. As of December 31, 2020, the Company has an accumulated deficit of $13,106,374. The Company had a net loss of $533,660 and $501,022 of net cash used in operations for the year ended December 31, 2020. These conditions raise substantial doubt about the company’s ability to continue as a going concern. The Company has historically relied upon unrelated and related party debt and equity financing to fund its cash flow shortages and will require either additional debt or equity financing to sustain its operations. The Company continues to seek funding from private debt and equity investors, as it needs to promptly raise substantial additional capital in order to finance its plan of operations. There can be no assurance that the Company will be able to promptly raise the necessary funds on commercially acceptable terms, if at all. If the Company does not raise the necessary funds, it may be forced to cease operations. These financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Policy Text Block [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company held no cash equivalents at December 31, 2020 and 2019. Accounts Receivable and Concentration Accounts receivable consist of balances due from assembly services with a related party. The Company monitors accounts receivable and provides allowances when considered necessary. At December 31, 2020 and 2019, accounts receivable were considered to be fully collectible. Accordingly, no allowance for doubtful accounts was provided. At December 31, 2020 and 2019, accounts receivable were due from one related customer. Revenue Recognition and Concentration The Company follows the revenue standards of Financial Accounting Standards Board Update No. 2014-09: “Revenue from Contracts with Customers (Topic 606).” The core principle of this Topic is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Revenue is recognized in accordance with that core principle by applying the following five steps: 1) identify the contracts with a customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to the performance obligations; and 5) recognize revenue when (or as) we satisfy a performance obligation. Royalties are recognized as earned in the period the sales to which the royalties relate occur. The Company has not yet generated any royalty revenues. Manufacturing assembly services are recognized as revenue when the assembled product is delivered to the customer and the Company has completed its performance obligations. Revenues for the years ended December 31, 2020 and 2019 were generated from manufacturing assembly services and are from one related customer. Impairment of Long-Lived Assets Impairment losses are recorded on long-lived assets (property, equipment and intellectual property) used in operations when impairment indicators are present and the undiscounted expected cash flows estimated to be generated by those assets are less than the carrying value of such assets. As of June 2019, the Company recognized an impairment loss of $69,178. The intellectual property was fully amortized as of December 31, 2019. The Company reviews intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company uses an estimate of the undiscounted cash flows over the remaining life of its long-lived assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment. Stock-based Compensation The Company has accounted for stock-based compensation under the provisions of Accounting Standards Codification (ASC) Topic 718 – “Stock Compensation” which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and common stock purchase warrants). The fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock options. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. Accounting for Uncertainty in Income Taxes The Company follows the provisions of ASC Topic 740-10, “Accounting for Uncertainty in Income Taxes” which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This topic also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. There is no uncertain tax positions as of December 31, 2020 and December 30, 2019. Income Tax Policy The Company accounts for income taxes using the liability method prescribed by ASC 740 - Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. Research and Development Costs The Company’s research and development costs are expensed in the period in which they are incurred. Such expenditures amounted to $114,559 and $218,919 for the years ended December 31, 2020 and 2019, respectively. Earnings (Loss) Per Share Earnings (loss) per share is computed in accordance with FASB ASC Topic 260, “Earnings per Share”. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. Certain common stock equivalents were not included in the earnings (loss) per share calculation as their effect would be anti-dilutive. Warrants exercisable for 950,000 and 975,000 shares as of December 31, 2020 and December 31, 2019, respectively, were excluded from weighted average common shares outstanding on a diluted basis as well as options for 12,180,500 shares. Financial Instruments The Company carries cash, accounts receivable, accounts payable, accrued expenses and convertible notes payable, at historical costs. The respective estimated fair values of these assets and liabilities approximate carrying values due to their short-term nature. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Reclassification Certain amounts in the 2019 financial statements have been reclassified to conform to the 2020 presentation with no impact to stockholders’ deficit or net loss.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2020
Recent Accounting Prouncements
Recent Accounting Pronouncements	Note 4 – Recent Accounting Pronouncements In August, 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, “Debt-Debt with Conversion and other options” which simplifies the accounting for convertible debt instruments and convertible preferred stock. The ASU is effective for public companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the impact ASU 2020-06 could have on its consolidated financial statements. There are several other new accounting pronouncements issued or proposed by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial position, operating results, or cash flows.

Intellectual Property and Licen

Intellectual Property and License Agreement	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Intellectual Property and License Agreement	Note 5 – Intellectual Property and License Agreement On June 1, 2016, the Company entered into a ten-year License Agreement with Helidyne LLC for total consideration of $100,000 to utilize the Helidyne intellectual property in the manufacturing of planetary rotor expanders and the incorporation of same in the Company’s distributed electric power generation systems. The license agreement also grants the Company an exclusive license to sell the expanders whether manufactured by Helidyne or by the Company. The Company’s royalty obligation begins on the earlier of the commercialization of the product or three years from the effective date of the agreement. Once the royalty obligation begins, the minimum annual royalty is $50,000 for each of the first six years, and $100,000, per commercial year, for the remainder of the agreement. Helidyne has defaulted under the agreement. Royalties would be payable only if Helidyne performs as required, or if the Company elects to produce its own expanders using Helidyne technology. In the second quarter of 2019, management of the Company evaluated the continued default by Helidyne and determined that Helidyne will not be able to perform under the license agreement for the foreseeable future. The Company’s license agreement continues to be active and the Company may utilize the Helidyne intellectual property in marketing its own products. Under the terms of the license agreement, the Company has the right to develop a prototype utilizing the Helidyne technology at its own cost. Due to the continued default by Helidyne and the potential cost of developing its own prototype, the Company has determined that the intangible asset related to the above license agreement is impaired and recognized an impairment charge of $69,178 in the second quarter of 2019, which is 100% of the net carrying value. For the years ended December 31, 2020 and 2019, amortization expense was $0 and $5,000, respectively.

Convertible Notes Payable to Re

Convertible Notes Payable to Related and Nonrelated Parties	12 Months Ended
	Dec. 31, 2020
Notes Payable to Related Parties
Convertible Notes Payable to Related and Nonrelated Parties	Note 6 - Convertible Notes Payable to Related Parties/Stockholders and Nonrelated Parties In January, March, and May 2019, the Company issued Convertible Notes Payable totaling $200,000 to related parties and stockholders and $100,000 convertible note payable to a nonrelated party. The notes are to be paid in one principal payment, along with any unpaid interest by December 31, 2021. Interest is payable semiannually at 10%. The notes are convertible into common stock at a price of $.20 per share through December 31, 2019, $.30 per share from January 1, 2020 through December 31, 2020, and $.40 per share from January 1, 2021 through the maturity date of December 31, 2021. In December 2019, the Company issued a Convertible Note Payable in the principal amount of $25,000 to a stockholder in connection with a loan in the same amount. The note is to be paid in one principal payment, along with any unpaid interest by December 31, 2022. Interest is payable semiannually at 10%. The note is convertible into common stock at a price of $.20 per share through December 31, 2020, $.30 per share from January 1, 2021 through December 31, 2021, and $.40 per share from January 1, 2022 through the maturity date of December 31, 2022. On December 4, 2020, the note along with accrued interest totaling $26,072 was converted into 130,362 shares of common stock. In March 2020, the Company issued a Convertible Note Payable in the principal amount of $100,000 to a nonrelated party in connection with a loan in the same amount. The note is to be paid in one principal payment, along with any unpaid interest by December 31, 2022. Interest is payable semiannually at 10%. The note is convertible into common stock at a price of $.20 per share through December 31, 2020, $.30 per share from January 1, 2021 through December 31, 2021, and $.40 per share from January 1, 2022 through the maturity date of December 31, 2022. In June 2020, the Company issued a Convertible Note Payable in the principal amount of $25,000 to a related party in connection with a loan in the same amount. The note is to be paid in one principal payment, along with any unpaid interest by July 31, 2023. Interest is payable semiannually at 10%. The note is convertible into common stock at a price of $.20 per share through December 31, 2020, $.30 per share from January 1, 2021 through December 31, 2021, and $.40 per share from January 1, 2022 through the maturity date of July 31, 2023. In the third quarter 2020, the Company issued Convertible Notes Payable totaling $511,000, of which $25,000 was with a stockholder and the remaining $486,000 was with nonrelated accredited investors in connection with loans for the same amount. The notes are to be paid in one principal payment, along with any unpaid interest by December 31, 2023. Interest is payable semiannually at 10% on June 30 and December 31. The notes are convertible into common stock at a price of $.20 per share through December 31, 2020, $.30 per share from January 1, 2021 through December 31, 2021, and $.40 per share from January 1, 2022 through the maturity date of December 31, 2023. In the fourth quarter 2020, the Company issued Convertible Notes Payable totaling $250,000, of which $75,000 was with a related party and stockholder and the remaining $175,000 was with nonrelated accredited investors in connection with loans for the same amount. The notes are to be paid in one principal payment, along with any unpaid interest by December 31, 2023. Interest is payable semiannually at 10% on June 30 and December 31. The notes are convertible into common stock at a price of $.20 per share through December 31, 2020, $.30 per share from January 1, 2021 through December 31, 2021, and $.40 per share from January 1, 2022 through the maturity date of December 31, 2023. Consequently, the Company has outstanding Convertible Notes Payable in an aggregate principal amount of $1,186,000 through December 31, 2020, of which $325,000 are due to related parties and stockholders, and $861,000 are to nonrelated parties (collectively referred to as the “Notes”). See Note 12 for further related party transactions. The Convertible Notes Payable that were issued in the third and fourth quarter 2020 included a beneficial conversion feature, which is recorded as a discount against the Notes and amortized through the earlier of the conversion into common stock, or the maturity date. Amortization of the debt discount is reported as interest expense in the Statement of Operations The total debt discount associated with the beneficial conversion feature for the year ended December 31, 2020 was $712,500. Total amortization associated with the beneficial conversion feature debt discount was $59,327 for the year ended December 31, 2020. Total debt issuance costs were $11,625 and $26,000 for the years ended December 31, 2020 and December 31, 2019, respectively. Total amortization associated with the debt issuance costs paid was $13,530 and $7,254 for the years ended December 31, 2020 and December 31, 2019, respectively. Convertible Notes Payable at December 31, 2020 and December 31, 2019 consisted of the following: December 31, December 31, 2020 2019 Current: Convertible notes payable to related parties and stockholders $ 200,000 $ — Less: Unamortized debt issuance costs 5,578 — Total convertible notes payable to related parties and stockholders $ 194,422 $ 0 Convertible notes payable $ 100,000 $ — Less: Unamortized debt issuance costs 2,824 — Total convertible notes payable, net $ 97,176 $ 0 Long Term: Convertible notes payable to related parties and stockholders $ 125,000 $ 225,000 Less: Unamortized debt discount - beneficial conversion feature 103,092 — Unamortized debt issuance costs 1,371 13,100 Total convertible notes payable to related parties and stockholders $ 20,536 $ 211,900 Convertible notes payable $ 761,000 $ 100,000 Less: Unamortized debt discount - beneficial conversion feature 550,080 — Unamortized debt issuance costs 7,069 5,646 Total convertible notes payable, net $ 203,851 $ 94,354

Warrants

Warrants	12 Months Ended
	Dec. 31, 2020
Warrants Abstract
Warrants	Note 7 – Warrants Warrants During September 2015, the Company issued five-year warrants to a stockholder for the purchase 25,000 shares of common stock at an exercise price of $.12 per share as additional consideration for a $25,000 loan. On September 30, 2020, the stockholder exercised the warrant for 25,000 shares at $0.12 per share, totaling $3,000. During June 2016, the Company issued warrants to a stockholder for the purchase of 900,000 shares of common stock at an exercise price of $0.11 per share in consideration for the Company utilizing his facility space from January 2013 to December 2015. These warrants expire in June 2021. As of December 31, 2020, all of these warrants were outstanding. In July 2016, a warrant for the purchase of 25,000 shares of common stock at an exercise price of $.19 per share was issued to a stockholder as additional consideration for a $25,000 loan. These warrants expire in July 2021. As of December 31, 2020, all of these warrants were outstanding. In October 2016, another warrant for the purchase of 25,000 shares of common stock was issued to the same stockholder at an exercise price of $.15 per share as additional consideration for extending the maturity of the $25,000 loan for an additional 90 days. These warrants expire in October 2021. As of December 31, 2020, all of these warrants were outstanding. 39 A summary of warrants issued, exercised and expired during the year ending December 31, 2020 is as follows: Shares Weighted Average Exercise Price Aggregate Intrinsic Value Balance at December 31, 2019 975,000 $ .11 $ 0 Exercised (25,000 ) .12 — Balance at December 31, 2020 950,000 $ .11 $ 690,500

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2020
Stock Options
Stock Options	Note 8 – Stock Options Stock option activity for the year ended December 31, 2020, is summarized as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Options outstanding and exercisable at December 31, 2019 12,180,500 $ 0.21 5.59 Options outstanding and exercisable at December 31, 2020 12,180,500 $ 0.21 4.63 Total stock option compensation was $0 and $80,000 for the years ended December 31, 2020 and 2019. There is no unrecognized compensation expense associated with the option.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Stockholders' Deficit	Note 9 – Stockholders’ Deficit On September 30, 2020, a shareholder exercised a warrant for 25,000 shares at $0.12 per share, totaling $3,000. The Company also purchased from George Konrad, the Company’s founder and former CEO and Director (“Konrad”) all of Konrad’s 4,027,408 shares of Company common stock (the “Shares”), representing 12.7% of the Company’s issued and outstanding common stock, for an aggregate price of $300,000 ($.074 per share). The Company raised the funds used for the purchase of the shares through a private placement of convertible notes to related parties, stockholders and non-related accredited investors (see Note 6). On December 4, 2020, a stockholder converted a Convertible Note Payable in the principal amount of $25,000 along with accrued interest totaling $26,072 into 130,362 shares of common stock (see Note 6).

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitment and Contingencies:
Commitments and Contingencies	Note 10 - Commitments and Contingencies On June 25, 2015, Company consultant Hank Leibowitz assigned to the Company a patent he obtained for a system and method for using high temperature sources in Rankine cycle power systems. The Company has agreed to pay Mr. Leibowitz a 2% royalty for any and all revenues of products and/or project sales by the Company based on the subject patent. At December 31, 2020, no royalties have been paid on this agreement. On September 20, 2020, the Company signed a Binding Letter of Intent for a merger (the “LOI”) with 374Water Inc. (“374Water”) a privately-held company based in Durham, North Carolina www.374water.com. Subject to the terms and conditions set forth in the LOI, 374Water will merge into a newly- formed wholly-owned subsidiary of the Company (the “Sub”), with the Sub as the surviving corporation (the “Merger”). Upon closing of the Merger, the Company will issue new shares of common stock to 374Water shareholders such that 374Water shareholders will own approximately 60% of the combined company, and the Company’s shareholders will own approximately 40%. The Merger is subject to adjustments for liabilities, and the closing is contingent on the achievement of certain milestones and satisfaction of conditions by both parties prior to closing, including the raising of net proceeds of at least $6.25 million of additional capital pursuant to a private placement by March 31, 2021. (See Note 13)

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Taxes:
Income Taxes	Note 11 – Income Taxes Deferred income taxes are provided based on the provisions of ASC Topic 740, “Accounting for Income Taxes”, to reflect the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Significant components of the Company’s net deferred income taxes are as follows: December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 1,953,623 1,773,162 Start-up cost 109,218 129,091 Goodwill 279,200 309,039 Stock based compensation 538,113 538,113 Other 16,636 1,079 Deferred tax assets 2,896,789 2,750,484 Less valuation allowance (2,896,789 ) (2,750,484 ) Net deferred tax assets after valuation allowance $ — — A reconciliation of the U.S. statutory federal income tax rate to the effective income tax rate (benefit) follows: Rate Reconciliation December 31, 2020 2019 Rate Reconciliation Federal income tax at statutory rate (112,069 ) (108,133 ) State Tax (18,795 ) (18,134 ) Change in Valuation Allowance 146,306 89,146 Permanent Differences 292 14,217 Other (15,734 ) 22,904 — — In assessing the ability to realize a portion of the deferred tax assets, management considers whether it is more than likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities and projected future taxable income in making the assessment. After consideration of the evidence, both positive and negative, management has determined that a $2,896,789 valuation allowance at December 31, 2020 is necessary. The change in the valuation allowance for the current year is $146,306, which represents the changes in the deferred items. At December 31, 2020, the Company has available net operating loss carry forwards for federal income tax purposes of $7,958,781 expiring at various times from 2028 through 2033.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions
Related Party Transactions	Note 12- Related Party Transactions From July 2010 until December 2017, the accounting firm J.L. Hofmann & Associates, P.A. (“JLHPA”), whose principal is our CFO John L. Hofmann, provided financial consulting and accounting services to the Company. In December 2017, J.L. Hofmann & Associates, P.A. merged with Kabat, Schertzer, De La Torre, Taraboulos & Co, LLC (“KSDT”). The Company paid $53,395 and $37,334 to KSDT for its services in the years ended December 31, 2020 and 2019, respectively. The Company’s consultant and shareholder Hank Leibowitz receives compensation of $7,500 per month, totaling $90,000 for the 2020. At December 31, 2020, Mr. Leibowitz was owed accrued compensation of $45,000, which is included in accounts payable and accrued expense on the accompanying balance sheets. On April 15, 2017, the Company entered into an assembly agreement with Liberty Plugins, Inc. (“Liberty”) to assemble Liberty’s Hydra electronic vehicle charging systems and ship completed Hydras to Liberty’s facility in Santa Barbara, California (the “Liberty Agreement”). Initially, Liberty agreed to pay $1,000 for the first 10 Hydras assembled in a month, $750 per Hydra for the next 10 Hydras assembled per month and $500 per Hydra for each Hydra assembled above 20 per month. The Company has never assembled/shipped more than 10 Hydras in any month and does not expect to do so in the future. Revenue for these products is reflected in the revenue –related party on the Company’s consolidated statement of operations and amounted to $40,000 and $24,000 for the years ended December 31, 2020 and 2019, respectively. The Liberty Agreement is subject to termination by either party on 30 days notice. The company’s CEO is a minority interest holder and member of the Board of Directors of Liberty. Therefore, transactions with Liberty have been disclosed as transactions with a related party. See Note 6 for convertible notes issued to related parties and Note 9 for repurchase of stock from a related party.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 13 – Subsequent Events As of March 5, 2021, the Company is holding in escrow $1,636,545 for purposes of the private placement required to generate net proceeds of $6.25 million as a condition of the closing of the Merger. (See Note 10)

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Policy Text Block [Abstract]
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company held no cash equivalents at December 31, 2020 and 2019.
Accounts Receivable and Concentration	Accounts Receivable and Concentration Accounts receivable consist of balances due from assembly services with a related party. The Company monitors accounts receivable and provides allowances when considered necessary. At December 31, 2020 and 2019, accounts receivable were considered to be fully collectible. Accordingly, no allowance for doubtful accounts was provided. At December 31, 2020 and 2019, accounts receivable were due from one related customer.
Revenue Recognition and Concentration	Revenue Recognition and Concentration The Company follows the revenue standards of Financial Accounting Standards Board Update No. 2014-09: “Revenue from Contracts with Customers (Topic 606).” The core principle of this Topic is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Revenue is recognized in accordance with that core principle by applying the following five steps: 1) identify the contracts with a customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to the performance obligations; and 5) recognize revenue when (or as) we satisfy a performance obligation. Royalties are recognized as earned in the period the sales to which the royalties relate occur. The Company has not yet generated any royalty revenues. Manufacturing assembly services are recognized as revenue when the assembled product is delivered to the customer and the Company has completed its performance obligations. Revenues for the years ended December 31, 2020 and 2019 were generated from manufacturing assembly services and are from one related customer.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Impairment losses are recorded on long-lived assets (property, equipment and intellectual property) used in operations when impairment indicators are present and the undiscounted expected cash flows estimated to be generated by those assets are less than the carrying value of such assets. As of June 2019, the Company recognized an impairment loss of $69,178. The intellectual property was fully amortized as of December 31, 2019. The Company reviews intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company uses an estimate of the undiscounted cash flows over the remaining life of its long-lived assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment.
Stock-based Compensation	Stock-based Compensation The Company has accounted for stock-based compensation under the provisions of Accounting Standards Codification (ASC) Topic 718 – “Stock Compensation” which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and common stock purchase warrants). The fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock options. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.
Accounting for Uncertainty in Income Taxes	Accounting for Uncertainty in Income Taxes The Company follows the provisions of ASC Topic 740-10, “Accounting for Uncertainty in Income Taxes” which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This topic also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. There is no uncertain tax positions as of December 31, 2020 and December 30, 2019.
Income Tax Policy	Income Tax Policy The Company accounts for income taxes using the liability method prescribed by ASC 740 - Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.
Research and Development Costs	Research and Development Costs The Company’s research and development costs are expensed in the period in which they are incurred. Such expenditures amounted to $114,559 and $218,919 for the years ended December 31, 2020 and 2019, respectively.
Earnings (Loss) Per Share	Earnings (Loss) Per Share Earnings (loss) per share is computed in accordance with FASB ASC Topic 260, “Earnings per Share”. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. Certain common stock equivalents were not included in the earnings (loss) per share calculation as their effect would be anti-dilutive. Warrants exercisable for 950,000 and 975,000 shares as of December 31, 2020 and December 31, 2019, respectively, were excluded from weighted average common shares outstanding on a diluted basis as well as options for 12,180,500 shares.
Financial instruments	Financial Instruments The Company carries cash, accounts receivable, accounts payable, accrued expenses and convertible notes payable, at historical costs. The respective estimated fair values of these assets and liabilities approximate carrying values due to their short-term nature.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.
Reclassification	Reclassification Certain amounts in the 2019 financial statements have been reclassified to conform to the 2020 presentation with no impact to stockholders’ deficit or net loss.

Convertible Notes Payable to _2

Convertible Notes Payable to Related Parties (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Payable to Related Parties
Convertible Notes Payable	Convertible Notes Payable at December 31, 2020 and December 31, 2019 consisted of the following: December 31, December 31, 2020 2019 Current: Convertible notes payable to related parties and stockholders $ 200,000 $ — Less: Unamortized debt issuance costs 5,578 — Total convertible notes payable to related parties and stockholders $ 194,422 $ 0 Convertible notes payable $ 100,000 $ — Less: Unamortized debt issuance costs 2,824 — Total convertible notes payable, net $ 97,176 $ 0 Long Term: Convertible notes payable to related parties and stockholders $ 125,000 $ 225,000 Less: Unamortized debt discount - beneficial conversion feature 103,092 — Unamortized debt issuance costs 1,371 13,100 Total convertible notes payable to related parties and stockholders $ 20,536 $ 211,900 Convertible notes payable $ 761,000 $ 100,000 Less: Unamortized debt discount - beneficial conversion feature 550,080 — Unamortized debt issuance costs 7,069 5,646 Total convertible notes payable, net $ 203,851 $ 94,354

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2020
Warrants Abstract
Summary of warrants	A summary of warrants issued, exercised and expired during the year ending December 31, 2020 is as follows: Shares Weighted Average Exercise Price Aggregate Intrinsic Value Balance at December 31, 2019 975,000 $ .11 $ 0 Exercised (25,000 ) .12 — Balance at December 31, 2020 950,000 $ .11 $ 690,500

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2020
Stock Options
Stock Option	Stock option activity for the year ended December 31, 2020, is summarized as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Options outstanding and exercisable at December 31, 2019 12,180,500 $ 0.21 5.59 Options outstanding and exercisable at December 31, 2020 12,180,500 $ 0.21 4.63

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Taxes:
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s net deferred income taxes are as follows: December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 1,953,623 1,773,162 Start-up cost 109,218 129,091 Goodwill 279,200 309,039 Stock based compensation 538,113 538,113 Other 16,636 1,079 Deferred tax assets 2,896,789 2,750,484 Less valuation allowance (2,896,789 ) (2,750,484 ) Net deferred tax assets after valuation allowance $ — —
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the U.S. statutory federal income tax rate to the effective income tax rate (benefit) follows: Rate Reconciliation December 31, 2020 2019 Rate Reconciliation Federal income tax at statutory rate (112,069 ) (108,133 ) State Tax (18,795 ) (18,134 ) Change in Valuation Allowance 146,306 89,146 Permanent Differences 292 14,217 Other (15,734 ) 22,904 — —

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Going Concern Details Narrative
Working capital deficit	$ (237,593)
Accumulated deficit	(13,106,374)	$ (12,572,714)
Net loss	(533,660)	(514,916)
Net cash used in operations	$ (502,022)	$ (287,449)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Allowance for doubtful accounts	$ 0	$ 0
Research and development cost	114,559	218,919
Loss on impairment	0	(69,178)
Uncertain tax positions	0	0
Cash equivalents	$ 0	$ 0
Warrants
Antidilutive Excluded from Computation of Earnings Per Share, Amount	950,000	975,000
Option
Antidilutive Excluded from Computation of Earnings Per Share, Amount	12,180,500

Intellectual Property and Lic_2

Intellectual Property and License Agreement (Details Narrative) - USD ($)	Jun. 02, 2016	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019
Amortization expense			$ 0	$ 5,000
Impairment charge		$ 69,178
Helidyne LLC [Member]
Commercial royalty obligation	$ 100,000
Annual royalty	$ 50,000

Convertible Notes Payable to _3

Convertible Notes Payable to Related Parties/Stockholders and Nonrelated Parties (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current:
Convertible notes payable	$ 100,000	$ 0
Unamortized debt issuance costs	2,824	0
Total convertible notes payable, net	97,176	0
Long Term:
Convertible notes payable	761,000	100,000
Unamortized debt discount - beneficial conversion feature	550,080	0
Unamortized debt issuance costs	7,069	5,646
Total convertible notes payable, net	203,851	94,354
Related Parties And Stockholders [Member]
Current:
Convertible notes payable	200,000	0
Unamortized debt issuance costs	5,578	0
Total convertible notes payable, net	194,422	0
Long Term:
Convertible notes payable	125,000	225,000
Unamortized debt discount - beneficial conversion feature	103,092	0
Unamortized debt issuance costs	1,371	13,100
Total convertible notes payable, net	$ 20,536	$ 211,900

Convertible Notes Payable to _4

Convertible Notes Payable to Related Parties/Stockholders and Nonrelated Parties (Details Narrative) - USD ($)	Dec. 04, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Sep. 30, 2020	May 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Notes payable to stockholders					$ 1,186,000			$ 1,186,000
Beneficial conversion feature								712,500
Amortization of debt discount								59,327
Debt issuance costs								11,625	$ 26,000
Amortization of debt issuance costs								13,530	7,254
Stockholder [Member]
Conversion of note payable and accrued interest, shares	130,362
Stockholder [Member] | Accrued Interest [Member]
Conversion of note payable and accrued interest, value	$ 26,072
Convertible Promissory Notes
Notes payable to stockholders							$ 200,000
Maturity date							Dec. 31, 2021
Notes payable description							The notes are convertible into common stock at a price of $.20 per share through December 31, 2019, $.30 per share from January 1, 2020 through December 31, 2020, and $.40 per share from January 1, 2021 through the maturity date of December 31, 2021.
Convertible Promissory Notes
Notes payable to stockholders				$ 25,000					$ 25,000
Maturity date				Dec. 31, 2022
Interest rate				10.00%					10.00%
Notes payable description				The notes are convertible into common stock at a price of $.20 per share through December 31, 2020, $.30 per share from January 1, 2021 through December 31, 2021, and $.40 per share from January 1, 2022 through the maturity date of December 31, 2022.
Convertible Promissory Notes
Notes payable to stockholders			$ 100,000
Maturity date			Dec. 31, 2022
Interest rate			10.00%
Notes payable description			The note is convertible into common stock at a price of $.20 per share through December 31, 2020, $.30 per share from January 1, 2021 through December 31, 2021, and $.40 per share from January 1, 2022 through the maturity date of December 31, 2022.
Convertible Promissory Notes
Notes payable to stockholders		$ 25,000				$ 511,000
Maturity date		Jul. 31, 2023				Dec. 31, 2023
Interest rate		10.00%				10.00%
Notes payable description		The note is convertible into common stock at a price of $.20 per share through December 31, 2020, $.30 per share from January 1, 2021 through December 31, 2021, and $.40 per share from January 1, 2022 through the maturity date of july 31, 2023.				The notes are convertible into common stock at a price of $.20 per share through December 31, 2020, $.30 per share from January 1, 2021 through December 31, 2021, and $.40 per share from January 1, 2022 through the maturity date of December 31, 2023.
Convertible Promissory Notes
Notes payable to stockholders					$ 250,000			$ 250,000
Maturity date					Dec. 31, 2023
Interest rate					10.00%			10.00%
Notes payable description					The notes are convertible into common stock at a price of $.20 per share through December 31, 2020, $.30 per share from January 1, 2021 through December 31, 2021, and $.40 per share from January 1, 2022 through the maturity date of December 31, 2023.

Warrants (Details)

Warrants (Details)	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Warrants Abstract
Balance at beginning | shares	975,000
Shares Exercised | shares	(25,000)
Balance at end | shares	950,000
Weighted Average Exercise Price Balance at beginning	$ 0.11
Weighted Average Exercise Price Exercised	.12
Weighted Average Exercise Price Balance at end	0.11
Aggregate Intrinsic Value Balance at beginning	$ 0
Aggregate Intrinsic Value Exercised | $	$ 0
Aggregate Intrinsic Value Balance at end	$ 690,500

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	Oct. 31, 2016	Jun. 30, 2016	Jul. 31, 2016	Sep. 30, 2015
Issuance of warrants to purchase common stock	25,000		25,000
Exercise price	$ 0.15		$ 0.19
Warrants expiration date	Oct. 31, 2021		Jul. 31, 2021
Additional consideration for loan	$ 25,000		$ 25,000
Stockholder [Member]
Issuance of warrants to purchase common stock		900,000		25,000
Exercise price		$ 0.11		$ 0.12
Warrants expiration date		Jun. 30, 2021
Additional consideration for loan				$ 25,000

Stock Options (Details)

Stock Options (Details) - Employee Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Shares
Options Outstanding, Begining Balance	12,180,500
Options Outstanding, Ending Balance	12,180,500	12,180,500
Options Exercisable Begining Balance	12,180,500
Options Exercisable Ending Balance	12,180,500	12,180,500
Weighted Average Exercise Price
Options Outstanding, Begining Balance, Weighted Average Exercise Price	$ 0.21
Options Outstanding, Ending Balance, Weighted Average Exercise Price	$ 0.21	$ 0.21
Weighted Average Remaining Contractual Life (Years)
Options outstanding Begining Balance	5 years 7 months 2 days	4 years 7 months 17 days
Options Exercisable, Begining Balance	5 years 7 months 2 days	4 years 7 months 17 days

Stock Options (Details Narrativ

Stock Options (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock-based compensation expense	$ 0	$ 80,000
Unrecognized stock-based compensation	$ 0

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Dec. 04, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Proceeds from warrant exercise		$ 3,000	$ 3,000	$ 0
Number of warrant exercised		25,000
Exercise price		$ 0.12
Repurchase of Common Stock Shares from related party, value			(300,000)
Stockholder [Member]
Stock issued for conversion, shares	130,362
Stockholder [Member] | Principal [Member]
Stock issued for conversion, value	$ 25,000
Stockholder [Member] | Accrued Interest [Member]
Stock issued for conversion, value	$ 26,072
Common Stock
Repurchase of Common Stock Shares from related party, value
Repurchase of Common Stock Shares from related party, Shares			(4,027,408)
Stock issued for conversion, shares			130,362

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	2 Months Ended
	Mar. 05, 2021	Jun. 25, 2015
Royalty percentage		2.00%
Subsequent Event [Member]
Proceeds from private placement	$ 6,250,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carryforwards	$ 1,953,623	$ 1,773,162
Start-up cost	109,218	129,091
Goodwill	279,200	309,039
Stock based compensation	538,113	538,113
Other	16,636	1,079
Deferred tax assets	2,896,789	2,750,484
Less valuation allowance	(2,896,789)	(2,750,484)
Net deferred tax assets after valuation allowance	$ 0	$ 0

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Rate Reconciliation
Federal income tax at statutory rate	$ (112,069)	$ (108,133)
State Tax	(18,795)	(18,134)
Change in Valuation Allowance	146,306	89,146
Permanent Differences	292	14,217
Other	(15,734)	22,904
Net deferred tax assets after valuation allowance	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Taxes:
Valuation allowance	$ 2,896,789	$ 2,750,484
Change in Valuation allowance	146,306
Net operating loss carry forwards for federal income tax purposes	$ 7,958,781
Net operating loss carry forwards for federal income tax purposes, expiration date	Expiring at various times from 2028 through 2033.

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Payments to related party	$ 53,395	$ 37,334
Revenue from product	40,000	$ 24,000
Hank Leibowitz
Compensation	90,000
Accrued compensation	$ 45,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	2 Months Ended
	Mar. 05, 2021USD ($)
Proceeds from private placement	$ 6,250,000
Escrow held	$ 1,636,545